Drug intelligence / Profile preview

BBRP11021

Development stage: Unknown
Lead developer: Benobio
Modality: Small Molecules

Overview

BBRP11021 is a small molecule antineoplastic drug under development by Benobio for the treatment of colorectal cancer and possibly pancreatic cancer. The precise mechanism of action has not been disclosed or remains undefined. As of the latest updates, it is a new molecular entity and has reached Phase 1 clinical trials in South Korea for colonic (colorectal) cancer, with preclinical or early clinical activity also suggested in pancreatic cancer. No orphan drug status or FDA designation has been granted to date[1][2][3].

Other names: BBRP 11021BBRP11021BBRP-11021

Targets

BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)BRD2 (Bromodomain-containing protein 2)

Beyond the preview

Go deeper on BBRP11021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBRP11021.

Explore the full profile